Gene therapy is a promising treatment option for hereditary deafness, and studies show that unilateral AAV1-hOTOF therapy is safe and associated with functional benefits.
Using the immunotherapy drug pembrolizumab before surgery instead of chemotherapy may improve outcomes for patients with stage 2 or 3 MMR-deficient colorectal cancer and MSI-H.